

# CDH3 Antibody (N-term) Blocking peptide

Synthetic peptide Catalog # BP1499a

## **Specification**

## CDH3 Antibody (N-term) Blocking peptide - Product Information

**Primary Accession** 

P22223

# CDH3 Antibody (N-term) Blocking peptide - Additional Information

**Gene ID 1001** 

#### **Other Names**

Cadherin-3, Placental cadherin, P-cadherin, CDH3, CDHP

### Target/Specificity

The synthetic peptide sequence used to generate the antibody <a href=/products/AP1499a>AP1499a</a> was selected from the C-term region of human CDH3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

#### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

## CDH3 Antibody (N-term) Blocking peptide - Protein Information

Name CDH3

Synonyms CDHP

#### **Function**

Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types.

#### **Cellular Location**

Cell membrane; Single-pass type I membrane protein

#### **Tissue Location**

Expressed in some normal epithelial tissues and in some carcinoma cell lines.



## CDH3 Antibody (N-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

### • Blocking Peptides

CDH3 Antibody (N-term) Blocking peptide - Images

## CDH3 Antibody (N-term) Blocking peptide - Background

CDH3 is a classical cadherin from the cadherin superfamily. It is a calcium-dependent cell-cell adhesion glycoprotein comprised of five extracellular cadherin repeats, a transmembrane region and a highly conserved cytoplasmic tail. Aberrant expression of this protein is observed in cervical adenocarcinomas. Mutations in the gene encoding CDH3 have been associated with congential hypotrichosis with juvenile macular dystrophy.

## CDH3 Antibody (N-term) Blocking peptide - References

Indelman, M., Clin. Exp. Dermatol. 32 (2), 191-196 (2007) Paredes, J., Clin. Cancer Res. 11 (16), 5869-5877 (2005)